Joint Recommendations of the Argentine Federation of Cardiology and the Argentine Society of Cardiology for the Use of Mineralocorticoid Receptor Antagonists in Heart Failure. Integrating Finerenone

Abstract

Heart failure (HF) is a common condition in the adult population. Approximately 64 million people suffer from it, and its prevalence varies between 1% and 3%, although among those over 65 years of age, it can reach 8.5% of the population. The Argentine Federation of Cardiology and the Argentine Society of Cardiology have deemed it appropriate to review the effects of nonsteroidal mineralocorticoid receptor antagonists (MRAs), especially finerenone, on HF, including both patients with HF and those at risk of developing it, such as diabetics and chronic kidney disease.